#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
GLP-1 Drugs in Children Ages 8-11: Trends
A 3.5-million-child Pediatrics study found GLP-1 prescriptions for 8-to-11-year-olds grew 310-fold from 2019 to 2026, all off-label.
GLP-1 Receptor Agonists and Sleep Apnea
Tirzepatide holds a US FDA approval for sleep apnea backed by SURMOUNT-OSA data. Here is what the evidence supports for the GLP-1 receptor agonist class.
Semaglutide, obesity, and chronic migraine
A 2026 letter in Headache argues semaglutide may break a loop in which obesity worsens migraine and fasting-driven avoidance triggers more attacks.
Semaglutide's direct reproductive effects
A 2026 rat study found semaglutide affects gonads beyond weight loss: androgens protected in males, reproductive hormones reduced in females.
Incretin drugs: outcomes before weight loss
A 2026 review ranks incretin therapies by CV mortality evidence first, weight loss second, and maps drug choice to patient phenotype via receptor pharmacology.
Lilly and the Medicare GLP-1 bridge program
The Medicare GLP-1 Bridge launched July 2026 at a $50 monthly copay. Lilly's Q2 numbers show the scale analysts are mapping against it.
A NAION case after semaglutide exposure
A 2026 case report describes NAION after recent semaglutide exposure. Here is what one case can show, and what it cannot.
Tirzepatide and unilateral Graves' disease
A 2026 case report describes unilateral Graves' disease developing in a patient with type 2 diabetes during tirzepatide treatment. No causal link established.
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.